Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A global, randomized Phase 3 registration trial with CRS-207 in combination with standard-of-care chemotherapy in patients with unresectable Malignant Pleural Mesothelioma (MPM)

Trial Profile

A global, randomized Phase 3 registration trial with CRS-207 in combination with standard-of-care chemotherapy in patients with unresectable Malignant Pleural Mesothelioma (MPM)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CRS 207 (Primary)
  • Indications Malignant-mesothelioma
  • Focus Registrational; Therapeutic Use
  • Sponsors Aduro BioTech

Most Recent Events

  • 12 Dec 2017 Status changed from planning to withdrawn prior to enrolment, according to an Adura Biotech media release
  • 21 Nov 2016 Status changed from suspended to planning, as according to an Aduro Biotech media release the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on its clinical trials evaluating the LADD (live, attenuated double-deleted) immunotherapy platform, enabling patient enrollment to resume in all Aduro-sponsored clinical studies.
  • 24 Oct 2016 Status changed from planning to suspended, as according to an Aduro Biotech media release, company has received notice from the U.S. FDA that the trials based on LADD (Listeria-based immunotherapy construct) platform have been placed on partial clinical hold to pause new patient enrollment as a metastatic pancreatic cancer patient with gastrointestinal symptoms tested positive for Listeria. Aduro is working with the FDA to lift the partial hold so as to resume new patient enrollment in its LADD.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top